



Original research



Prognostic impact of selection criteria of current adjuvant endocrine therapy trials NATALEE and monarchE in postmenopausal HRpos/HER2neg breast cancer patients treated with upfront letrozole

Peter A. Fasching^{a,*}, Carolin C. Hack^{a,1}, Naiba Nabieva^a, Nicolai Maass^b, Bahriye Aktas^c, Sherko Kümmel^d, Christoph Thomssen^e, Christopher Wolf^f, Hans-Christian Kolberg^g, Cosima Brucker^h, Wolfgang Janniⁱ, Peter Dall^j, Andreas Schneeweiss^k, Frederik Marme^l, Marc W. Sütterlin^l, Matthias Ruebner^a, Anna-Katharin Theuser^m, Sara Kellner^a, Nadine M. Hofmann^m, Sybille Böhm^m, Katrin Almstedt^{a,n}, Hans-Joachim Lück^o, Sabine Schmatloch^p, Matthias Kalder^q, Christoph Uleer^r, Ingolf Jurhasz-Böss^s, Volker Hanf^t, Christian Jackisch^u, Volkmar Müller^v, Brigitte Rackⁱ, Erik Belleville^w, Diethelm Wallwiener^x, Achim Rody^y, Claudia Rauh^{a,z}, Christian M. Bayer^{a,aa}, Sabrina Uhrig^a, Chloë Goossens^a, Hanna Huebner^a, Sara Y. Brucker^x, Alexander Hein^{ab}, Tanja N. Fehm^{ac,ad}, Lothar Häberle^{a,ae}

^a Department of Gynecology and Obstetrics, Comprehensive Cancer Center Erlangen-EMN, University Hospital Erlangen, Friedrich-Alexander-Universität Erlangen-Nürnberg, Erlangen, Germany

^b Department of Gynecology and Obstetrics, University Hospital of Schleswig-Holstein, Campus Kiel, Kiel, Germany

^c Department of Gynecology, University Hospital Leipzig, Leipzig, Germany

^d Interdisziplinäres Brustzentrum an den Kliniken Essen-Mitte, Essen, Germany

^e Department of Gynaecology, Martin-Luther-University Halle-Wittenberg, Halle (Saale), Germany

^f Medical Center Ulm, Ulm, Germany

^g Department of Gynecology and Obstetrics, Marienhospital Bottrop, Bottrop, Germany

^h Department of Gynecology and Obstetrics, University Hospital, Paracelsus Medical University, Nuremberg, Germany

ⁱ Department of Gynecology and Obstetrics, Ulm University Hospital, Ulm, Germany

^j Department of Obstetrics and Gynecology, Municipal Clinical Center, Lüneburg, Germany

^k National Center for Tumor Diseases (NCT), Heidelberg University Hospital and German Cancer Research Center, Heidelberg, Germany

^l Department of Gynecology and Obstetrics, University Medical Centre Mannheim, Medical Faculty Mannheim, Heidelberg University, Mannheim, Germany

^m Institut für Frauengesundheit GmbH, Erlangen, Germany

ⁿ Department of Obstetrics and Gynecology, University Medical Center Mainz, Johannes Gutenberg University, Mainz, Germany

^o Gynäkologisch-Onkologische Praxis Hannover, Hannover, Germany

^p Elisabeth Krankenhaus Kassel, Kassel, Germany

^q Department of Gynecology and Obstetrics, University Hospital Gießen and Marburg, Marburg, Germany

^r Gyn.-onkologische Gemeinschaftspraxis Hildesheim, Hildesheim, Germany

^s Department of Obstetrics and Gynecology, Freiburg University Hospital, Freiburg, Germany

^t Frauenklinik, Klinikum Fürth, Fürth, Germany

^u Frauenklinik Sana Klinikum, Offenbach, Germany

^v Department of Gynecology, Hamburg-Eppendorf University Medical Center, Hamburg, Germany

^w ClinSol GmbH & Co KG., Würzburg, Germany

^x Department of Obstetrics and Gynecology, University of Tuebingen, Tuebingen, Germany

^y Department of Gynecology and Obstetrics, University Hospital Schleswig-Holstein, Campus Lübeck, Lübeck, Germany

^z Department of Gynecology, University Hospital Inselspital Bern, Bern, Switzerland

^{aa} WMC HEALTHCARE GmbH, München, Germany

^{ab} Department of Gynecology and Obstetrics, Klinikum Esslingen, Esslingen, Germany

^{ac} Department of Gynecology and Obstetrics, University Hospital Düsseldorf, Düsseldorf, Germany

^{ad} Centrum für Integrierte Onkologie Aachen Bonn Köln Düsseldorf, Düsseldorf, Germany

^{ae} Biostatistics Unit, Erlangen University Hospital, Department of Gynecology and Obstetrics, Comprehensive Cancer Center Erlangen-EMN, Friedrich-Alexander University Erlangen-Nuremberg, Germany

* Corresponding author.

E-mail address: peter.fasching@uk-erlangen.de (P.A. Fasching).

¹ these authors contributed equally.

<https://doi.org/10.1016/j.ejca.2024.114239>

Available online 21 July 2024

0959-8049/© 2024 The Authors. Published by Elsevier Ltd. This is an open access article under the CC BY license (<http://creativecommons.org/licenses/by/4.0/>).

ARTICLE INFO

Keywords:

Early breast cancer
Hormone therapy
Letrozole
Aromatase inhibitors
Prognosis
CDK4/6 inhibitors

ABSTRACT

Background: The monarchE and NATALEE trials demonstrated the benefit of CDK4/6 inhibitor (CDK4/6i) therapy in adjuvant breast cancer (BC) treatment. Patient selection, based on clinical characteristics, delineated those at high (monarchE) and high/intermediate recurrence risk (NATALEE). This study employed a historical patient cohort to describe the proportion and prognosis of patients eligible for adjuvant CDK4/6i trials.

Methods: Between 2009 and 2011, 3529 patients were enrolled in the adjuvant PreFace clinical trial (NCT01908556). Eligibility criteria included postmenopausal patients with hormone receptor-positive (HRpos) BC for whom a five-year upfront therapy with letrozole was indicated. Patients were categorized into prognostic groups according to monarchE and NATALEE inclusion criteria, and their invasive disease-free survival (iDFS) and overall survival (OS) were assessed.

Results: Among 2891 HRpos patients, 384 (13.3 %) met the primary monarchE inclusion criteria. The majority (n = 261) qualified due to having ≥ 4 positive lymph nodes. For NATALEE, 915 out of 2886 patients (31.7 %) met the eligibility criteria, with 126 patients (13.7 %) being node-negative. Patients from monarchE with ≥ 4 positive lymph nodes and NATALEE with stage III BC exhibited the poorest prognosis (3-year iDFS rate 0.87). Patients ineligible for the trials demonstrated prognoses similar to the most favorable patient groups within the eligibility criteria.

Conclusion: Patient populations eligible for monarchE and NATALEE trials differed. Nearly a third of the postmenopausal HRpos population, previously under upfront letrozole treatment, met the NATALEE prognostic eligibility criteria. As certain eligible groups had a prognosis similar to non-eligible patients, it might be interesting to explore additional patient groups for CDK4/6i therapy.

1. Introduction

The therapeutic landscape for patients diagnosed with hormone receptor-positive (HRpos) breast cancer (BC) has shown continuous improvement ever since tamoxifen's introduction nearly 50 years ago. Aromatase inhibitors (AI) and tamoxifen form the cornerstone of all adjuvant treatment modalities for HRpos BC patients. National and international guidelines advocate for adjuvant endocrine therapy comprising at least 2–3 years of AI treatment for postmenopausal patients [1–4]. Evidence on these therapies stems from studies comparing five years of tamoxifen, AI therapy, or their sequential administration, along with trials examining the duration of endocrine treatment [5–13].

A meta-analysis pooling data from nine adjuvant BC trials revealed that five-year AI treatment resulted in a 3.6 % lower absolute recurrence risk than five-year tamoxifen treatment. Sequential tamoxifen and AI therapy exhibited a 2 % lower absolute recurrence risk compared to tamoxifen alone. Moreover, initiating sequential endocrine therapy with an AI displayed an approximate 30 % lower recurrence risk in the initial two years than initiating with tamoxifen [14]. Consequently, upfront AI therapy emerges as an advisable standard for postmenopausal patients with HRpos BC. Despite the current widespread implementation of upfront AI therapy for postmenopausal patients, its initial introduction prompted discussions regarding the potential limitations of the benefit derived from a five-year AI therapy or a sequential tamoxifen-AI therapy, particularly for patients with high recurrence risk and tamoxifen contraindications [15,16].

Recently introduced by the monarchE study, CDK4/6 inhibitors (CDK4/6i) offer a new therapeutic option for adjuvant treatment in higher-risk patients with early-stage HRpos/HER2neg BC. Currently, abemaciclib stands as the sole CDK4/6i approved for early HRpos/HER2neg BC, specifically for patients at increased recurrence risk [17–19]. Eligibility criteria dictated a requirement of either at least four positive lymph nodes or 1–3 positive lymph nodes alongside an additional risk factor [17]. Moreover, the NATALEE study, using ribociclib, reported favorable outcomes concerning invasive disease-free survival (iDFS) [20]. The NATALEE trial encompassed nodal positive patients and included node-negative patients with either a tumor size of T3/T4 or node-negative patients with a T2 tumor size and a tumor grading of three or a high genomic risk profile [20]. Consequently, it is generally inferred that monarchE enrolled HRpos/HER2neg patients at high risk, whereas NATALEE encompassed both high-risk and intermediate-risk populations. However, studies failed to establish superior benefit

among subgroups based on high or lower risk profiles [17–20].

Limited knowledge exists regarding the distribution of patient groups eligible for CDK4/6i trials. Within the postmenopausal setting, a cohort of patients treated upfront with an AI presents an ideal opportunity to explore both prognosis and the prevalence of respective risk factors. Therefore, this study aimed to utilize data from the phase IV PreFace study to investigate the prognosis and prevalence of subgroups eligible for inclusion in either monarchE or NATALEE.

2. Methods**2.1. PreFace clinical trial**

The PreFace study (Evaluation of PREDictive FACTors Regarding the Effectivity of AI Therapy, NCT01908556) constituted a prospective open-label phase IV clinical trial conducted across Germany between 2009 and 2016. Ethics Committee Approval was obtained from the Medical Faculty of the Friedrich-Alexander University Erlangen-Nuremberg and all involved ethics committees. Written informed consent was obtained from all patients.

Postmenopausal patients with HRpos early BC were eligible if their attending physician recommended adjuvant upfront letrozole treatment for a duration of five years according to the summary of product characteristics (SmPC) for letrozole. No specific requirements regarding a particular risk profile were mandated. Letrozole treatment was recommended to begin as soon as possible after final surgery or completion of (neo)adjuvant chemotherapy. Patient visits were scheduled at 6 months, 12 months, 24 months and 60 months. The primary outcome measures encompassed iDFS and overall survival (OS). iDFS was defined as the period from the date of therapy begin to either the earliest date of disease progression (invasive local, regional, and distant recurrences; contralateral breast cancer; second non-breast primary cancer; and death from any cause) or to the last date the patient was known to be disease free. OS was defined in a similar fashion. The primary analysis has been already published elsewhere [21].

2.2. Patients

HRpos BC patients who initiated letrozole treatment and had information available from at least one study visit were selected from the 3529 patients enrolled into the PreFace study. These patients were evaluated for eligibility concerning the monarchE and NATALEE trials




Fig. 1. Patient flow chart (CONSORT Diagram) *HRpos*: hormone receptor-positive, *pts.*: patients, *HER2pos*: HER2-positive, *HER2neg*: HER2-negative, *LN*: lymph nodes.

[19,20]. Patients with missing information precluding eligibility assessment for monarchE or NATALEE were excluded from further analysis. For monarchE, patients were categorized into one of the following groups: [≥ 4 positive lymph nodes], [1–3 positive lymph nodes and tumor grading of 3], [1–3 positive lymph nodes and a tumor > 5 cm] or [none of these monarchE groups/not eligible]. Regarding NATALEE, patients were allocated to one of the following groups: [AJCC Stage III], [AJCC Stage IIB], [AJCC Stage IIA with negative lymph nodes but a tumor grading of 3], [AJCC Stage IIA and positive lymph nodes], or [none of these NATALEE groups/not eligible]. Subsequently, iDFS and OS from the PreFace study were evaluated based on the constructed monarchE- and NATALEE-like patient groups.

2.3. Statistical methods

Continuous patient and tumor characteristics were summarized using means and standard deviations, while ordinal and categorical characteristics were presented as frequencies and percentages. Survival rates with 95 % confidence intervals (CIs) were estimated via the Kaplan-Meier product limit method. Patients who started therapy before entering the PreFace study were not at risk with regard to iDFS from therapy begin to study entry (“immortal time”). iDFS was therefore left-

truncated for time to enter the study, if the entry was after therapy begin, and right-censored at the end of study. OS was handled similarly.

All calculations were performed out using R (version 3.0.1; R Development Core Team, Vienna, Austria, 2013).

3. Results

3.1. Patients and eligibility for monarchE or NATALEE

Out of the initially registered 3529 PreFace patients, 632 subjects were excluded (Fig. 1). Consequently, the total study population for this analysis comprised 2897 patients. Among these, 2891 possessed sufficient clinical data for monarchE criteria assessment, while 2886 had adequate data for NATALEE criteria evaluation. Within the respective cohort, 384 patients (13.3 %) met monarchE eligibility, whereas 915 patients out of 2886 (31.7 %) met NATALEE criteria (Fig. 1).

Patient characteristics corresponding to different inclusion groups for monarchE (≥ 4 positive lymph nodes; 1–3 positive lymph nodes; 1–3 positive lymph nodes and a tumor size > 5 cm; or not eligible) are outlined in Table 1. Similarly, Table 2 shows the patient characteristics according to the NATALEE criteria (stage III; stage IIB; stage IIA (N0 with G3); Stage IIA (N1); or not eligible). Disregarding tumor size,

Table 1
Patient characteristics of subgroups based on monarchE inclusion criteria (N = 2891 patients).

Characteristic		Mean and SD or frequency and percent			
		not eligible (N = 2507)	≥ 4 LN (N = 261)	1–3 LN, G3 (N = 97)	1–3 LN, T > 5cm (N = 26)
Age at study entry (years)	mean (SD)	64.0 (7.4)	63.7 (8.4)	63.8 (9.2)	64.4 (8.3)
	median (IQR)	63.9 (58.4, 69.2)	63.2 (57.7, 69.7)	63.0 (57.0, 70.0)	64.6 (59.3, 70.9)
	< 65	1354 (54.2)	153 (58.6)	57 (58.8)	13 (50.0)
	≥ 65	1144 (45.8)	108 (41.4)	40 (41.2)	13 (50.0)
BMI (kg/m ²)	mean (SD)	27.1 (5.1)	27.7 (5.8)	26.5 (4.6)	28.0 (4.6)
	median (IQR)	26.3 (23.7, 29.8)	26.6 (23.5, 30.1)	26.2 (23.4, 28.8)	28.0 (25.0, 31.2)
	< 20	98 (4.0)	8 (3.1)	7 (7.3)	0 (0.0)
	20–25	834 (33.6)	85 (32.9)	30 (31.2)	5 (19.2)
	25–30	940 (37.9)	98 (38.0)	44 (45.8)	13 (50.0)
	≥ 30	608 (24.5)	67 (26.0)	15 (15.6)	8 (30.8)
Lymph node status	pN0	2044 (82.3)	0 (0.0)	0 (0.0)	0 (0.0)
	pN+	440 (17.7)	261 (100.0)	97 (100.0)	26 (100.0)
Tumor stage	pT0	20 (0.8)	1 (0.4)	2 (2.1)	0 (0.0)
	pT1	1761 (70.4)	64 (24.5)	35 (36.1)	0 (0.0)
	pT2	668 (26.7)	134 (51.3)	57 (58.8)	0 (0.0)
	pT3	31 (1.2)	53 (20.3)	0 (0.0)	26 (100.0)
	pT4	22 (0.9)	9 (3.4)	3 (3.1)	0 (0.0)
	G1	552 (22.0)	14 (5.4)	0 (0.0)	2 (7.7)
Grading	G2	1702 (68.0)	173 (66.8)	0 (0.0)	19 (73.1)
	G3	250 (10.0)	72 (27.8)	97 (100.0)	5 (19.2)
	ER-	26 (1.0)	4 (1.5)	3 (3.1)	0 (0.0)
Estrogen receptor (ER) status	ER+	2478 (99.0)	256 (98.5)	94 (96.9)	26 (100.0)
	PgR-	286 (11.4)	41 (15.8)	22 (22.7)	5 (19.2)
Progesterone receptor (PgR) status	PgR+	2220 (88.6)	219 (84.2)	75 (77.3)	21 (80.8)
	*ER-/PgR-	5 (0.2)	0 (0.0)	0 (0.0)	0 (0.0)
Hormone receptor (HR) status	ER-/PgR+	21 (0.8)	4 (1.5)	3 (3.1)	0 (0.0)
	ER+ /PgR-	280 (11.2)	41 (15.8)	22 (22.7)	5 (19.2)
	ER+ /PgR+	2197 (87.8)	215 (82.7)	72 (74.2)	21 (80.8)
	ductal	1818 (72.7)	179 (68.8)	81 (83.5)	11 (42.3)
Histology	lobular	443 (17.7)	60 (23.1)	11 (11.3)	12 (46.2)
	other	241 (9.6)	21 (8.1)	5 (5.2)	3 (11.5)
	neoadjuvant	122 (4.9)	33 (12.7)	10 (10.4)	9 (34.6)
Prior chemotherapy	adjuvant	582 (23.5)	197 (75.8)	67 (69.8)	13 (50.0)
	neoadjuvant and adjuvant	4 (0.2)	2 (0.8)	0 (0.0)	0 (0.0)
	naive	1768 (71.4)	28 (10.8)	19 (19.8)	4 (15.4)

SD standard deviation, IQR interquartile range, BMI body mass index, LN: lymph nodes

*positive hormone receptor status at the time of diagnosis and conversion after neoadjuvant chemotherapy

grading, and nodal status, no major differences were observed between the monarchE eligibility groups. One only notable disparity appeared in histology, where 46.2 % of patients with 1–3 lymph nodes and a tumor larger than 5 cm exhibited lobular histology (Table 1). Likewise, no major differences were evident among the eligibility groups of the NATALEE study (Table 2).

Among 2885 patients assessed against both monarchE and NATALEE criteria, 1942 (67.3 %) did not meet the eligibility for either study. Moreover, 559 patients (19.4 %) met NATALEE but not monarchE criteria, while 29 patients (1 %) met monarchE but not NATALEE criteria. Additionally, 355 patients (12.3 %) met eligibility for both trials.

3.2. Outcome parameters and eligibility for monarchE or NATALEE

Given the increased recurrence risk as the main rationale for expanding adjuvant endocrine treatment with an additional two years of abemaciclib or an additional three years of ribociclib, we estimated iDFS and OS rates based on eligibility groups for both studies. Within the PreFace study, median follow-up time for iDFS was 59.5 months (interquartile ranges (IQR) 37.9–62.5) and for OS 59.7 months (IQR 48.7–62.9).

There was a clear difference in iDFS between patients with more than four positive lymph nodes (3-year iDFS rate: 0.87 [95 %CI: 0.82–0.91]) and those ineligible for monarchE (3-year iDFS rate: 0.95 [95 %CI: 0.94–0.96]) (Table 3). However, all other monarchE patient groups displayed similar iDFS rates to the non-eligible group (patients with 1–3 positive lymph nodes: 0.93 [95 %CI: 0.88–0.99]; patients with 1–3

positive lymph nodes and a tumor larger than 5 cm: 0.94 [95 %CI: 0.84–1.00]). The 3-year iDFS rate for the combined eligible group was 0.89 [95 %CI: 0.86–0.92] (Table 3). Corresponding Kaplan-Meier curves are depicted in Figs. 2 and S1A. A similar pattern was observed for OS (Table 4). Kaplan-Meier curves are presented in Figs. 3 and S1C.

Regarding the NATALEE eligibility groups, patients deemed ineligible exhibited the most favorable prognosis (3-year iDFS rate: 0.96 [95 %CI: 0.95–0.97]), whereas those with Stage III disease had the poorest prognosis (3-year iDFS rate: 0.87 [95 %CI: 0.82–0.91]). Notably, the most favorable prognostic group eligible for NATALEE were stage IIA patients with positive lymph nodes, showcasing a 3-year iDFS rate of 0.93 (95 %CI: 0.90–0.96). The 3-year iDFS rate for the combined eligible group was 0.90 [95 %CI: 0.88–0.92] (Table 3). Corresponding Kaplan-Meier curves are presented in Figs. 4 and S1B. In the NATALEE groups, OS rates displayed a similar pattern to iDFS, albeit with smaller differences between groups (Table 4). Kaplan-Meier curves are presented in Figs. 5 and S1D.

4. Discussion

Using a historical patient cohort treated with upfront AI therapy, we revealed a substantial proportion meeting the eligibility criteria for the major adjuvant CDK4/6i trials monarchE (13.3 % of HRpos/HER2neg PreFace Patients) and NATALEE (31.7 % of all PreFace patients). Most eligible patients showed a worse prognosis compared to patients who were not eligible. However, the difference in prognosis between the best prognostic groups in patients eligible for the studies and those not eligible was not large. Consequently, it might be interesting to further

Table 2

Patient characteristics of subgroups based on NATALEE inclusion criteria (N = 2886 patients) [SD standard deviation, BMI body mass index IQR interquartile range] *positive hormone receptor status at the time of diagnosis and conversion after neoadjuvant chemotherapy.

Characteristic		Mean and SD or frequency and percent				
		Not eligible (N = 1971)	Stage III (N = 261)	Stage IIB (N = 262)	Stage IIA: N0, G3 (N = 95)	Stage IIA: N1 (N = 297)
Age at study entry (years)	mean (SD)	63.9 (7.2)	63.7 (8.4)	64.9 (8.7)	66.7 (8.1)	63.5 (8.1)
	median (IQR)	63.7 (58.3, 69)	63.2 (57.7, 69.7)	64.2 (58.5, 71.2)	66.7 (60.4, 72.2)	63.8 (57.8, 68.9)
	< 65	1077 (54.9)	153 (58.6)	135 (51.5)	42 (44.7)	165 (55.7)
	≥ 65	886 (45.1)	108 (41.4)	127 (48.5)	52 (55.3)	131 (44.3)
BMI (kg/m ²)	mean (SD)	27.1 (5.1)	27.7 (5.8)	27.4 (5.0)	27.8 (4.9)	27.0 (5.1)
	median (IQR)	26.3 (23.6, 29.8)	26.6 (23.5, 30.1)	26.8 (24.0, 29.9)	27.1 (24.8, 30.0)	26.1 (23.2, 29.7)
	< 20	85 (4.4)	8 (3.1)	8 (3.1)	2 (2.2)	10 (3.4)
	20 – 25	666 (34.1)	85 (32.9)	75 (29.2)	23 (25.0)	104 (35.4)
	25 – 30	725 (37.1)	98 (38.0)	110 (42.8)	43 (46.7)	116 (39.5)
	≥ 30	478 (24.5)	67 (26.0)	64 (24.9)	24 (26.1)	64 (21.8)
Lymph node status	pN0	1913 (98.2)	0 (0.0)	31 (11.8)	95 (100.0)	0 (0.0)
	pN+	36 (1.8)	261 (100.0)	231 (88.2)	0 (0.0)	297 (100.0)
	pT0	17 (0.9)	1 (0.4)	0 (0.0)	0 (0.0)	5 (1.7)
Tumor stage	pT1	1504 (76.3)	64 (24.5)	0 (0.0)	0 (0.0)	292 (98.3)
	pT2	399 (20.2)	134 (51.3)	231 (88.2)	95 (100.0)	0 (0.0)
	pT3	26 (1.3)	53 (20.3)	31 (11.8)	0 (0.0)	0 (0.0)
	pT4	25 (1.3)	9 (3.4)	0 (0.0)	0 (0.0)	0 (0.0)
	G1	465 (23.6)	14 (5.4)	24 (9.2)	0 (0.0)	63 (21.3)
Grading	G2	1348 (68.5)	173 (66.8)	173 (66.0)	0 (0.0)	196 (66.2)
	G3	155 (7.9)	72 (27.8)	65 (24.8)	95 (100.0)	37 (12.5)
	ER-	17 (0.9)	4 (1.5)	3 (1.1)	5 (5.3)	4 (1.3)
Estrogen receptor (ER) status	ER+	1951 (99.1)	256 (98.5)	259 (98.9)	90 (94.7)	293 (98.7)
	PgR-	237 (12.0)	41 (15.8)	30 (11.5)	18 (18.9)	28 (9.4)
Progesteron receptor (PgR) status	PgR+	1733 (88.0)	219 (84.2)	232 (88.5)	77 (81.1)	269 (90.6)
	*ER-/PgR-	2 (0.1)	0 (0.0)	1 (0.4)	1 (1.1)	1 (0.3)
	ER-/PgR+	15 (0.8)	4 (1.5)	2 (0.8)	4 (4.2)	3 (1.0)
	ER+ /PgR-	234 (11.9)	41 (15.8)	29 (11.1)	17 (17.9)	27 (9.1)
Hormone receptor (HR) status	ER+ /PgR+	1716 (87.2)	215 (82.7)	230 (87.8)	73 (76.8)	266 (89.6)
	ductal	1400 (71.1)	179 (68.8)	181 (69.3)	78 (83.0)	246 (82.8)
	lobular	362 (18.4)	60 (23.1)	70 (26.8)	9 (9.6)	24 (8.1)
	other	206 (10.5)	21 (8.1)	10 (3.8)	7 (7.4)	27 (9.1)
Prior chemotherapy	neoadjuvant	80 (4.1)	33 (12.7)	20 (7.7)	9 (9.6)	29 (9.8)
	adjuvant	280 (14.4)	197 (75.8)	171 (65.8)	49 (52.1)	163 (55.1)
	neoadjuvant and adjuvant	2 (0.1)	2 (0.8)	0 (0.0)	0 (0.0)	2 (0.7)
	naive	1581 (81.4)	28 (10.8)	69 (26.5)	36 (38.3)	102 (34.5)

explore additional patient groups that could potentially benefit from respective CDK4/6i treatments.

We discussed both the monarchE (adjuvant abemaciclib) and NATALEE (adjuvant ribociclib) studies. It has to be noted that, at the time of writing, only abemaciclib has received approval in the adjuvant setting. The escalation of adjuvant endocrine treatment in both trials (NATALEE and monarchE) targeted patient groups with increased recurrence risk. Implementing inclusion and exclusion criteria focusing on high recurrence risk patients serves various potential reasons. One rationale could be to optimize study design by selecting patients with higher event rates, potentially reducing time and patient numbers required to prove new treatment efficacy. Additionally, patients with a high recurrence risk might exhibit the greatest unmet need for prognosis

improvement, wherein varying levels of benefit could exist. However, in monarchE, there was no indication that the relative benefit would be larger in patients with higher recurrence risk [17]. Subgroup analyses based on positive lymph nodes, grading, tumor size, and AJCC tumor stage only showed effects in hazard ratios among subgroups based on tumor size. Patients with smaller tumors (< 2 cm) displayed greater benefit (HR=0.48; 95 %CI: 0.36–0.65) compared to those with tumors between 2 and 5 cm (HR=0.75; 95 %CI: 0.62–0.92) or larger tumors (> 5 cm; HR=0.69; 95 %CI: 0.52–0.91) [17]. The interaction p-value for subgroup comparisons was 0.044 [17]. Initially, a hypothesis suggesting higher benefit among patients with high Ki-67 from cell cycle-inhibiting treatments existed, but this was disproven. Abemaciclib's efficacy remained comparable irrespective of Ki-67 status, where Ki-67 emerged

Table 3

Invasive disease-free survival (iDFS) rates relative to the subgroups of the monarchE and NATALEE trials.

Study	Subgroup	N	Events	2-year iDFS rate (95 % CI)	3-year iDFS rate (95 % CI)	5-year iDFS rate (95 % CI)
monarchE	monarchE ≥ 4 LN	261	57	0.91 (0.88, 0.95)	0.87 (0.82, 0.91)	0.76 (0.70, 0.82)
	monarchE 1 – 3 LN, G3	97	12	0.97 (0.93, 1.00)	0.93 (0.88, 0.99)	0.87 (0.80, 0.95)
	monarchE 1 – 3 LN, T > 5 cm	26	3	1.00 (1.00, 1.00)	0.94 (0.84, 1.00)	0.82 (0.65, 1.00)
	monarchE (all categories)	384	72	0.93 (0.91, 0.96)	0.89 (0.86, 0.92)	0.79 (0.75, 0.84)
	not eligible	2507	201	0.96 (0.95, 0.97)	0.95 (0.94, 0.96)	0.91 (0.90, 0.92)
NATALEE	NATALEE stage III	261	57	0.91 (0.88, 0.95)	0.87 (0.82, 0.91)	0.76 (0.70, 0.82)
	NATALEE stage IIB	262	34	0.95 (0.92, 0.97)	0.91 (0.88, 0.95)	0.86 (0.81, 0.91)
	NATALEE stage IIA: N0, G3	95	12	0.92 (0.86, 0.98)	0.91 (0.84, 0.97)	0.85 (0.78, 0.93)
	NATALEE stage IIA: N1	297	27	0.95 (0.93, 0.98)	0.93 (0.90, 0.96)	0.89 (0.85, 0.93)
	NATALEE (all categories)	915	130	0.94 (0.92, 0.95)	0.90 (0.88, 0.92)	0.84 (0.81, 0.87)
	not eligible	1971	143	0.97 (0.96, 0.98)	0.96 (0.95, 0.97)	0.92 (0.91, 0.93)

CI confidence interval; LN: lymph nodes




Fig. 2. Invasive disease-free survival relative to monarchE inclusion subgroups. *Black curve:* patients not eligible for monarchE; *red curve:* eligible monarchE patients with ≥ 4 positive lymph nodes (LN); *green curve:* eligible monarchE patients with 1–3 positive LN and a grade 3 tumor; *blue curve:* eligible monarchE patients with 1–3 positive LN and a tumor size (T) > 5 cm.

as a good prognostic factor [18]. Subgroup analyses in the NATALEE study found no differences in relative efficacy based on AJCC-stage, histological grade, Ki-67 status, or nodal status [20]. Thus, although focusing on high-risk patient populations might offer benefits, it does not imply inefficiency of a certain medication in patients with lower risk profiles.

In our analysis of the HRpos/HER2neg subset, we observed that most patients eligible for monarchE had four or more positive lymph nodes. A minority had 1–3 lymph nodes (with a tumor grading of 3 or a tumor > 5 cm), showing a prognosis similar to those ineligible for monarchE. This prompts us to hypothesize whether other patient groups might benefit from abemaciclib treatment. However, node-negative patients, absent in the monarchE study, constitute a substantial portion of postmenopausal patients with HRpos/HER2neg early BC. In NATALEE, over 600 node-negative patients were included, with their relative treatment benefit showing more prominence numerically (HR = 0.63; 95 %CI: 0.34–1.16) compared to patients with positive lymph nodes (HR = 0.77; 95 %CI: 0.63–0.94) [20]. This supports the potential efficacy of CDK4/6i in patients across varied recurrence risk profiles. In our patient population, the prognosis of all patients eligible for either monarchE or

NATALEE was comparable to each other (NATALEE-eligible: 3-year iDFS rate: 0.90 [95 %CI: 0.88–0.92]; monarchE-eligible 3-year iDFS rate: 0.89 [95 %CI: 0.86–0.92]). In the monarchE trial, 3-year iDFS rate was 84.4 % in patients receiving endocrine therapy alone [17], while in the NATALEE trial, 3-year iDFS rate was 87.1 % in patients who received nonsteroidal aromatase inhibitor alone [20]. Accordingly, the PreFace patient population eligible for enrollment into monarchE and NATALEE had a more favorable prognosis than the corresponding patient population of the pivotal trials themselves.

In both analyses, patients who did not fulfill the study criteria exhibited an excellent prognosis, with 5-year OS rates of 0.96 (95 %CI: 0.96–0.97; monarchE) and 0.97 (95 %CI: 0.96–0.98; NATALEE). This suggests that these patient populations might not necessitate an escalation of adjuvant endocrine treatment. However, within this cohort with a favorable prognosis, there might be subgroups warranting consideration for intensified therapy by incorporating CDK4/6i. Notably, patients undergoing abemaciclib and ribociclib treatments experience additional therapy management demands and side effects that might affect their quality of life during the extended 2- or 3-year treatment period. Around 20 % of patients discontinued CDK4/6i

Table 4
Overall survival (OS) rates relative to the subgroups of the monarchE and NATALEE trials.

Study	Subgroup	N	Events	2-year OS rate (95 % CI)	3-year OS rate (95 % CI)	5-year OS rate (95 % CI)
monarchE	monarchE ≥ 4 LN	261	33	0.97 (0.94, 0.99)	0.94 (0.91, 0.97)	0.86 (0.81, 0.91)
	monarchE 1–3 LN, G3	97	7	0.99 (0.97, 1.00)	0.98 (0.95, 1.00)	0.92 (0.87, 0.99)
	monarchE 1–3 LN, T > 5 cm	26	2	1.00 (1.00, 1.00)	1.00 (1.00, 1.00)	0.87 (0.72, 1.00)
	monarchE (all categories)	384	42	0.97 (0.96, 0.99)	0.96 (0.93, 0.98)	0.88 (0.84, 0.91)
	not eligible	2507	82	0.99 (0.98, 0.99)	0.98 (0.97, 0.99)	0.96 (0.96, 0.97)
NATALEE	NATALEE stage III	261	33	0.97 (0.94, 0.99)	0.94 (0.91, 0.97)	0.86 (0.81, 0.91)
	NATALEE stage IIB	262	18	0.97 (0.95, 0.99)	0.97 (0.94, 0.99)	0.92 (0.89, 0.96)
	NATALEE stage IIA: N0, G3	95	6	0.96 (0.92, 1.00)	0.96 (0.92, 1.00)	0.92 (0.87, 0.98)
	NATALEE stage IIA: N1	297	16	0.97 (0.95, 0.99)	0.96 (0.94, 0.99)	0.94 (0.91, 0.97)
	NATALEE (all categories)	915	73	0.97 (0.96, 0.98)	0.96 (0.94, 0.97)	0.91 (0.89, 0.93)
	not eligible	1971	51	0.99 (0.99, 1.00)	0.99 (0.98, 0.99)	0.97 (0.96, 0.98)

CI confidence interval; LN: lymph nodes

therapy in both monarchE and NATALEE due to adverse events [18,20]. Therefore, managing CDK4/6i treatment in the adjuvant setting poses challenges. Extending the indication to patients with a lower recurrence risk would require monitoring persistence and adherence across

prognostic groups. A large study with AI suggested that persistence was not solely related to side effects but also to patients’ prognostic profiles [22,23]. Patients with a more unfavorable prognosis exhibited higher persistence compared to those with a better prognosis [22,23]. Hence,




Fig. 3. Overall survival relative to monarchE inclusion subgroups. *Black curve:* patients not eligible for monarchE; *red curve:* eligible monarchE patients with ≥ 4 positive lymph nodes (LN); *green curve:* eligible monarchE patients with 1–3 positive LN and a grade 3 tumor; *blue curve:* eligible monarchE patients with 1–3 positive LN and a tumor size (T) > 5 cm.




Fig. 4. Invasive disease-free survival relative to NATALEE inclusion subgroups. *Black curve:* patients not eligible for NATALEE; *red curve:* eligible NATALEE patients AJCC stage III; *green curve:* eligible NATALEE patients with AJCC stage IIB; *blue curve:* eligible NATALEE patients with AJCC stage IIA, with negative lymph nodes and a grade 3 tumor; *purple curve:* eligible NATALEE patients with AJCC stage IIA and positive lymph nodes.

addressing individual patient prognosis and side effects becomes crucial to offer optimal therapy management, maintaining quality of life, and achieving the best CDK4/6i treatment effects.

Our study has certain limitations. First, this analysis is retrospective, even though the clinical data was collected prospectively. Additionally, there is a selection bias, as only postmenopausal patients were included in the PreFace trial, whereas patient populations in the adjuvant CDK4/6i trials comprised both premenopausal and postmenopausal individuals. The difference in prognosis between all PreFace patients eligible for monarchE and NATALEE and the reported prognosis in the monarchE and NATALEE trials could potentially be due to not having premenopausal patients in our patient population. Within the PreFace trial’s postmenopausal population, patients were enrolled if their treating physicians recommended upfront therapy with AIs. During the recruitment for the PreFace study, upfront AI therapy was not the standard for all patients. Those with a lower risk profile might have rather been treated with a sequential treatment of tamoxifen and AIs, while those with a higher risk of recurrence were considered for upfront

AI therapy [15,16]. Consequently, the PreFace study might have gathered a patient cohort with an elevated risk of recurrence. However, there is one other study that calculated the proportion of monarchE and NATALEE patients in a cohort of all-comers and calculated rates of 18.1 % for monarchE and 42.9 % for NATALEE, which lies in the range of our study [24]. Nevertheless, it has to be kept in mind that stage distribution in our study is from a country in which mammography screening was available at the time of the study conduct. It has been described that stage distribution might differ greatly between countries and regions [25].

In conclusion, using a historical patient population treated with upfront AI, we revealed that 13.3 % and 31.7 % of patients would have met the eligibility criteria for the monarchE and NATALEE studies, respectively. Among the eligible patient cohorts, certain subgroups exhibited prognoses comparable to those ineligible for the studies. Given the efficacy of CDK4/6i in both higher and lower recurrence risk patients, this data suggests that exploration into additional patient groups that could benefit from CDK4/6i treatment may be of interest.




Fig. 5. Overall survival relative to NATALEE inclusion subgroups. *Black curve*: patients not eligible for NATALEE; *red curve*: eligible NATALEE patients AJCC stage III; *green curve*: eligible NATALEE patients with AJCC stage IIB; *blue curve*: eligible NATALEE patients with AJCC stage IIA, with negative lymph nodes and a grade 3 tumor; *purple curve*: eligible NATALEE patients with AJCC stage IIA and positive lymph nodes.

Funding

Partial funding for the clinical trial was provided by Novartis Germany GmbH. The company had no influence on data collection, assembly, analysis, or the content of this paper.

CRedit authorship contribution statement

Volker Hanf: Investigation. **Bahriye Aktas**: Investigation. **Ingolf Jurhasz-Böss**: Investigation. **Christoph Uleer**: Investigation. **Lothar Häberle**: Visualization, Methodology, Formal analysis. **Sybille Böhm**: Project administration. **Tanja N. Fehm**: Investigation. **Nadine M. Hofmann**: Project administration. **Alexander Hein**: Investigation. **Sara Kellner**: Investigation. **Sara Y. Brucker**: Investigation. **Anna-Katharin Theuser**: Project administration. **Matthias Kalder**: Investigation. **Carolin C. Hack**: Writing – original draft, Supervision, Project administration, Investigation. **Sabine Schmatloch**: Investigation. **Peter A. Fasching**: Writing – review & editing, Writing – original draft, Supervision, Resources, Project administration, Investigation, Funding acquisition, Conceptualization. **Hans-Joachim Lück**: Investigation.

Katrin Almstedt: Investigation. **Nicolai Maass**: Investigation. **Naiba Nabieva**: Investigation. **Hanna Huebner**: Writing – original draft, Investigation. **Matthias Ruebner**: Investigation. **Chloë Goossens**: Writing – review & editing, Writing – original draft. **Marc W Sütterlin**: Investigation. **Sabrina Uhrig**: Data curation. **Christian M. Bayer**: Investigation. **Erik Belleville**: Project administration. **Hans-Christian Kolberg**: Investigation. **Brigitte Rack**: Investigation. **Christopher Wolf**: Investigation. **Volkmar Müller**: Investigation. **Christoph Thomssen**: Investigation. **Christian Jackisch**: Investigation. **Sherko Kümmel**: Investigation. **Andreas Schneeweiss**: Investigation. **Claudia Rauh**: Investigation. **Peter Dall**: Investigation. **Achim Rody**: Investigation. **Wolfgang Janni**: Investigation. **Diethelm Wallwiener**: Investigation. **Cosima Brucker**: Investigation. **Frederik Marme**: Investigation.

Declaration of Competing Interest

The authors declare the following financial interests/personal relationships which may be considered as potential competing interests: P. A.F. reports grants from Biontech and Cepheid, personal fees from

Novartis, Pfizer, Daiichi Sankyo, AstraZeneca, Eisai, MSD, Lilly, Pierre Fabre, SeaGen, Roche, Hexal, Agendia, Gilead. C.C.H. received honoraria from AstraZeneca, Daiichi Sankyo, Eisai, Novartis, Pfizer, Roche, Gilead and MSD, and travel grants from Daiichi-Sankyo. N.N. is an employee of Novartis Pharma GmbH. B.A. received honoraria from AstraZeneca, Gilead, Genomic Health, Roche, Novartis, Celgene, Lilly, MSD, Eisai, Stemline, Teva, Tesaro, Daiichi Sankyo and Pfizer. Received travel grants from AstraZeneca, Roche, Novartis, Celgene, Lilly, Eisai, Stemline, Daiichi Sankyo and Pfizer. Participated in the data safety monitoring board or advisory boards for AstraZeneca, Gilead, Genomic Health, Roche, Novartis, Celgene, Lilly, MSD, Eisai, Tesaro, Daiichi Sankyo and Pfizer. S.K. received honoraria from Amgen, Celgene, Daiichi Sankyo, Novartis and Roche. C.T. received honoraria for advisory boards and lectures from Amgen, AstraZeneca, Celgene, Daiichi Sankyo, Eisai, Gilead, Lilly, MSD, Mylan, Nanostring, Novartis, Pfizer, Pierre Fabre, Puma, Roche, Seagen, Vifor. H.-C.K. received honoraria from Pfizer, Novartis, Roche, Genomic Health/Exact Sciences, Amgen, AstraZeneca, Riemsler, Carl Zeiss Meditec, TEVA, Theraclion, Janssen-Cilag, GSK, LIV Pharma, Lilly, Daiichi Sankyo, Gilead and Zuellig, travel support from Carl Zeiss Meditec, LIV Pharma, Novartis, Amgen, Pfizer, Daiichi Sankyo, Tesaro, Gilead, AstraZeneca, Zuellig, and Stemline, participated in data safety monitoring or advisory boards for Pfizer, Novartis, SurgVision, Carl Zeiss Meditec, Amgen, Onkowsissen, MSD, Gilead, Daiichi Sankyo, Seagen, Genomic Health/Exact Sciences, Agendia, Lilly and owns stock of Theraclion SA. W.J. has received research grants and/or honoraria from Sanofi-Aventis, Daiichi Sankyo, Novartis, Roche, Pfizer, Lilly, AstraZeneca, Chugai, GSK, Eisai, Celgene and Johnson&Johnson. A.S. reported grants from Celgene, Roche and AbbVie. Personal fees from Celgene, Roche, Pfizer, AstraZeneca, Novartis, MSD, Tesaro, Lilly, Seagen, Gilead, GSK, Bayer, Amgen, and Pierre Fabre, and travel grants from Celgene, Roche, Pfizer and AstraZeneca. F.M. received honoraria from Amgen, AstraZeneca, Celgene, Clovis Oncology, CureVac, Eisai, Genomic Health, GSK, Immunomedics, Janssen-Cilag, Lilly, MSD, Novartis, Pfizer, PharmaMar, Roche, Seattle Genetics, Tesaro. M.W.S. received honoraria from AstraZeneca, Pfizer, Clovis, Mylan, Roche, Gedeon Richter, Carl Zeiss Meditec, travel support from Pfizer, Carl Zeiss Meditec. C.J. reports personal fees from AstraZeneca, Exact Sciences, Lilly, Novartis and Roche. V.M. received speaker honoraria from AstraZeneca, Daiichi Sankyo, Eisai, Pfizer, MSD, Medac, Novartis, Roche, Seagen, Onkowsissen, high5 Oncology, Medscape, Gilead, Pierre Fabre, iMED Institut. Consultancy honoraria: Roche, Pierre Fabre, PINK, ClinSol, Novartis, MSD, Daiichi Sankyo, Eisai, Lilly, Seagen, Gilead, Stemline. Institutional research support from Novartis, Roche, Seagen, Genentech, AstraZeneca. Travel grants from AstraZeneca, Roche, Pfizer, Daiichi Sankyo, Gilead. C.R. received honoraria from MSD and AstraZeneca, travel expenses from the Swiss Society of Senology and the Swiss Society of Gynecology. P.D. received honoraria from MSD, Pierre Fabre, Novartis, AstraZeneca, Lilly, Gilead, Pfizer, Roche. E.B. received honoraria from Novartis, Hexal, BMS, Lilly, Pfizer, Roche, MSD, Bayer, Ipsen, Bluebird, B. Braun and onkowsissen.de for consulting, clinical research management or medical education activities. S.Y.B. has received honoraria from Roche Pharma, Novartis, Pfizer, MSD, Teva, AstraZeneca. T.N.F. has received honoraria from Novartis, Roche, Pfizer, TEVA, Daiichi Sankyo, AstraZeneca and MSD. All of the remaining authors have declared that they do not have any conflicts of interest.

Appendix A. Supporting information

Supplementary data associated with this article can be found in the online version at [doi:10.1016/j.ejca.2024.114239](https://doi.org/10.1016/j.ejca.2024.114239).

References

- [1] National Comprehensive Cancer Network (NCCN), NCCN Clinical Practice Guidelines in Oncology (NCCN Guidelines) Breast Cancer Version 3.2022. https://www.nccn.org/professionals/physician_gls/pdf/breast.pdf, 2022; p. accessed June 18, 2022.
- [2] Ditsch N, et al. AGO Recommendations for the Diagnosis and Treatment of Patients with Early Breast Cancer: Update 2021. *Breast Care (Basel)* 2021;16(3):214–27.
- [3] Loibl S, et al. Early breast cancer: ESMO Clinical Practice Guideline for diagnosis, treatment and follow-up. *Ann Oncol* 2024;35(2):159–82.
- [4] Burstein HJ, et al. Adjuvant Endocrine Therapy for Women With Hormone Receptor-Positive Breast Cancer: ASCO Clinical Practice Guideline Focused Update. *J Clin Oncol* 2019;37(5):423–38.
- [5] Goss PE, et al. Exemestane versus anastrozole in postmenopausal women with early breast cancer: NCIC CTG MA.27—a randomized controlled phase III trial. *J Clin Oncol* 2013;31(11):1398–404.
- [6] Boccardo F, et al. Switching to anastrozole versus continued tamoxifen treatment of early breast cancer: preliminary results of the Italian Tamoxifen Anastrozole Trial. *J Clin Oncol* 2005;23(22):5138–47.
- [7] Jakesz R, et al. Switching of postmenopausal women with endocrine-responsive early breast cancer to anastrozole after 2 years' adjuvant tamoxifen: combined results of ABCSG trial 8 and ARNO 95 trial. *Lancet* 2005;366(9484):455–62.
- [8] Kaufmann M, et al. Improved overall survival in postmenopausal women with early breast cancer after anastrozole initiated after treatment with tamoxifen compared with continued tamoxifen: the ARNO 95 Study. *J Clin Oncol* 2007;25(19):2664–70.
- [9] Baum M, et al. Anastrozole alone or in combination with tamoxifen versus tamoxifen alone for adjuvant treatment of postmenopausal women with early-stage breast cancer: results of the ATAC (Arimidex, Tamoxifen Alone or in Combination) trial efficacy and safety update analyses. *Cancer* 2003;98(9):1802–10.
- [10] Coombes RC, et al. A randomized trial of exemestane after two to three years of tamoxifen therapy in postmenopausal women with primary breast cancer. *N Engl J Med* 2004;350(11):1081–92.
- [11] van de Velde CJ, et al. Adjuvant tamoxifen and exemestane in early breast cancer (TEAM): a randomised phase 3 trial. *Lancet* 2011;377(9762):321–31.
- [12] Dubsky PC, et al. Tamoxifen and anastrozole as a sequencing strategy: a randomized controlled trial in postmenopausal patients with endocrine-responsive early breast cancer from the Austrian Breast and Colorectal Cancer Study Group. *J Clin Oncol* 2012;30(7):722–8.
- [13] Baum M, et al. Anastrozole alone or in combination with tamoxifen versus tamoxifen alone for adjuvant treatment of postmenopausal women with early breast cancer: first results of the ATAC randomised trial. *Lancet* 2002;359(9324):2131–9.
- [14] Early Breast Cancer Trialists' Collaborative Group. Aromatase inhibitors versus tamoxifen in early breast cancer: patient-level meta-analysis of the randomised trials. *Lancet* 2015;386(10001):1341–52.
- [15] Bedard PL, Piccart-Gebhart MJ. Progress in tailoring adjuvant endocrine therapy for postmenopausal women with early breast cancer. *Curr Opin Oncol* 2009;21(6):491–8.
- [16] Chlebowski RT. Optimizing aromatase inhibitor integration into initial treatment strategies in postmenopausal women with hormone-receptor-positive early breast cancer. *Breast Cancer Res Treat* 2008;112(Suppl 1):25–34.
- [17] Johnston SRD, et al. Abemaciclib plus endocrine therapy for hormone receptor-positive, HER2-negative, node-positive, high-risk early breast cancer (monarchE): results from a preplanned interim analysis of a randomised, open-label, phase 3 trial. *Lancet Oncol* 2023;24(1):77–90.
- [18] Harbeck N, et al. Adjuvant abemaciclib combined with endocrine therapy for high-risk early breast cancer: updated efficacy and Ki-67 analysis from the monarchE study. *Ann Oncol* 2021;32(12):1571–81.
- [19] Johnston SRD, et al. Abemaciclib Combined With Endocrine Therapy for the Adjuvant Treatment of HR+, HER2-, Node-Positive, High-Risk, Early Breast Cancer (monarchE). *J Clin Oncol* 2020;JCO2002514.
- [20] Slamon D, et al. Ribociclib plus Endocrine Therapy in Early Breast Cancer. *N Engl J Med* 2024;390(12):1080–91.
- [21] Hack CC, et al. Long-term Follow-up and Safety of Patients after an Upfront Therapy with Letrozole for Early Breast Cancer in Routine Clinical Care - The PreFace Study. *Geburtshilfe Frau* 2024;84(2):185–95.
- [22] Nabieva N, et al. Influence of side-effects on early therapy persistence with letrozole in post-menopausal patients with early breast cancer: Results of the prospective EvAluate-TM study. *Eur J Cancer* 2018;96:82–90.
- [23] Nabieva N, et al. Influence of patient and tumor characteristics on early therapy persistence with letrozole in postmenopausal women with early breast cancer: results of the prospective Evaluate-TM study with 3941 patients. *Ann Oncol* 2018;29(1):186–92.
- [24] Schaffler H, et al. The Clinical Relevance of the NATALEE Study: Application of the NATALEE Criteria to a Real-World Cohort from Two Large German Breast Cancer Centers. *Int J Mol Sci* 2023;24(22).
- [25] Benitez Fuentes JD, et al. Global Stage Distribution of Breast Cancer at Diagnosis: A Systematic Review and Meta-Analysis. *JAMA Oncol* 2023.